. Although CD8 + T cells that target HIV-1 epitopes that are restricted by these alleles are thought to be protective, multiple studies have shown that relative or complete control of viral replication can occur in spite of the presence of escape mutations [4] [5] [6] . The prototypical example of this is the T242N mutation in the Gag TW10 epitope. This mutation provides effective escape from the HLA-B*57/58-specific cytotoxic T lymphocyte (CTL) response, but it does not correlate with a loss of control of viremia, raising the question of how critical the CTL response is in the maintenance of viral control. Evaluating the temporal relationship between the development of escape mutations in HLA-B*57/5801-restricted epitopes and the control of viral replication at a genomewide level would help determine the relevance of the CTL response in slowing progression to AIDS.
In this study, we documented the transmission of HIV-1 from a patient with progressive disease to an HLA-B*5801-positive individual. Full genome sequence analysis of isolates obtained from both individuals allowed us to determine for what may be the first time the extent of mutations in HLA-B*5801-restricted epitopes compared with the rest of the HIV-1 proteome. Additionally, longitudinal sequence data of specific genes, combined with enzyme-linked immunospot assay (ELI-SPOT) analysis of critical epitopes and mutations within them, provided us with a more thorough perspective on the importance of escape in HIV-1 infection.
Methods. The transmitter patient was a 45-year-old man with progressive HIV-1 infection and a history of injection drug use. He had a peak viral load of 53,000 copies/mL and a CD4 cell nadir of 207 cells/mL. He was not on highly active antiretroviral therapy (HAART) when the transmission occurred. His HLA alleles are HLA-A*300101, HLA-A*330301, HLA-B*4201, and HLA-B*530101. Transmission from the transmitter patient to the subject patient, a 35-year-old woman who was positive for HLA-A*300101, HLA-A*680101, HLA-B*5801, and HLA-B*5802, occurred after unprotected heterosexual vaginal intercourse in August 2006. The subject patient developed an influenza-like illness in early September of that year. An HIV-1 test taken on 18 August 2006 had a negative result, but a repeat test taken on 25 October 2006 had a positive result. The date of transmission was estimated to be 15 August 2006. The first viral load and CD4 cell count of the subject patient, obtained on day 102 after infection, had values of 4940 copies/ mL and 816 cells/mL, respectively. On day 137 after infection, the viral load had a value of 1159 copies/mL, and the CD4 cell count had a value of 655 cells/mL. The viral load reached a set Freshly isolated peripheral blood mononuclear cells (PBMCs) from the subject patient were stimulated with overlapping 15-mer peptides obtained from the National Institutes of Health AIDS Research and Reference Reagent Program as described elsewhere [5] .
Genomic DNA and plasma RNA isolation was performed as described elsewhere [5] . The genes nef, pol, and gag were amplified from provirus in genomic DNA by limiting dilution "digital" nested polymerase chain reaction (PCR) to prevent resampling [5] . Reverse-transcription PCR was performed from plasma and serum samples as described elsewhere [5] .
Epitopes were defined on the basis both of peptides to which the patients responded in our ELISPOT analysis and of epitopes that were documented for these patients' HLA-A and HLA-B alleles on the CTL epitope map in the Los Alamos HIV database (http://www.hiv.lanl.gov). The term "reversion" refers to differences in which the virus evolved from an apparent escape mutation in the transmitter patient back to the B Clade consensus sequence in the subject patient. "Diversion" mutations refer to substitutions that were different both from the transmitter patient's virus and from the B Clade consensus sequences; these mutations likely represent escape in the subject patient's HLA-restricted epitopes. For analysis of the Env mutation, we excluded sites at which the alignment was ambiguous (including portions of V1/V2 and V4/V5). All sequences have been submitted to GenBank (GQ256628-GQ256646).
Results. To confirm that the 2 patients were indeed a transmission pair, we amplified plasma virus from both patients at day 221 after transmission and compared full-length HIV-1 isolates. The dominant plasma sequences of Vif, Vpr, Vpu, and Tat and of protease were identical in the 2 patients, providing strong evidence that the virus was transmitted to the subject patient by her partner, the transmitter patient. Interestingly, almost half of the substitutions in the subject patient can be explained by the virus evolving in response to pressure from the CTL of the 2 patients. Four diversion mutations were located in HLA-B*5801-restricted epitopes, whereas 6 were in epitopes restricted by other HLA alleles ( Table 1) . Reversion of potential escape mutations was seen in 3 epitopes that were potentially targeted by the transmitter patient at some point. Overall, 13 of the 27 differences between the predominant plasma virus amplified from the transmitter patient and that from the subject patient were present in CTL epitopes that were potentially targeted by either patient. This analysis clearly indicates that the CTL response has a strong influence on viral evolution.
Because of the importance of the HLA-B*5801 allele in viral control, mutations present in HLA-B*57/5801-restricted epitopes are of particular interest. We amplified and sequenced gag from plasma of the transmitter patient and near-full-length gag from a serum sample from the subject patient on day 67 of infection. There were only 3 differences that distinguished the dominant Gag sequences of the 2 patients, including T242N, a mutation in the HLA-B*5801-restricted epitope TW10 ( Figure 1B) . Inspection of sequence chromatograms revealed double peaks (A and C) at nucleotide position 725 (the codon with the C peak results in wild-type T242, whereas the mutant codon with the A peak results in the expression of T242N). Thus, it appears that evolution from the wild-type sequence to T242N was occurring at this time point. We were unable to amplify nef or pol at day 67 due to limited sample availability. However, all 3 genes were amplified from plasma and resting CD4 + T cells at later time points ( Figure 1B) . At day 137, the predominant Nef sequence in plasma contained an F90L substitution in KF9. By day 221, this had been replaced by virus containing the well-characterized A83G escape mutation [7] as well as a V85L substitution in KF9, and virus containing just the V85L mutation was also detected. This might reflect selection for a more fit isolate, because the F90L mutation is extremely rare. More than 99.5% of all HIV-1 Nef sequences from all different clades in the Los Alamos database have phenylalanine (F) at position 90, and the F90L mutation is seen in just 1 other B Clade isolate. In contrast, isolates with A83G and V85L are frequently observed.
The transmitter patient had 2 distinct plasma isolates with threonine (T) or alanine (A) at position 124 in integrase. The predominant plasma virus in the subject patient had A at this position, but at day 137 a T125M mutation was detected in the SW10 epitope in some isolates. This mutant later became the dominant plasma and proviral sequence ( Figure 1B) .
To determine whether the substitutions in the HLA-B*5801-restricted epitopes were escape mutations, we performed ELI-SPOT analysis to compare wild-type and autologous variants of epitopes, using PBMCs sampled 2 years after infection. As shown in Figure 1C , there was still a robust response to wildtype TW10, but the response to the escape mutant was minimal. We observed a greater response to the transmitter patient's variant of the SW10 epitope than to the variant that developed in the subject patient, which suggests the latter variant was an escape mutant. In contrast, there was no detectable response to any of the 3 Nef KF9 variants that were tested. Thus, early escape may have led to a dramatic decline in the frequency of Figure 1 . A, Summary of the subject patient's plasma human immunodeficiency virus type 1 (HIV-1) RNA level and CD4 cell count over time. Arrows indicate critical events. B, Evolution in HLA-B*5801-restricted epitopes in plasma and serum (population sequences) or provirus (clonal sequences) at day 67 (D67), day 137 (D137), day 221 (D221), and day 256 (D256) after infection. C, Enzyme-linked immunospot assay analysis, with peripheral blood mononuclear cells (PBMCs) sampled 2 years after infection, of key epitopes in which mutation occurred in the patient. Shown are the results of analysis of the TW10 Gag epitope (top), KF9 Nef epitope (middle), and SW9 integrase epitope (bottom) and peptides containing the mutations seen in the patient. HAART, highly active antiretroviral therapy; SFC, spot-forming cell.
cells specific for the transmitted variant. The use of PBMCs sampled 2 years after infection may have also caused us to miss early responses to the escape mutants, especially because the HIV-specific immune response can be affected by HAART.
There was substantial evolution in epitopes restricted by alleles other than HLA-B*5801 in the subject patient. Of the 3 differences seen in Gag on day 67, 2 were within 3 overlapping HLA-B*53-restricted epitopes. Sequencing of the 3 end of the gene on day 137 revealed 2 more changes in HLA-B*53 epitopes ( Table 1) . Most of these changes likely represent reversion of escape mutations that occurred in the HLA-B*53-positive transmitter patient (Table 1 ). In addition, on day 221 there were changes that probably represented reversion in other epitopes that were targeted by the transmitter patient and diversion within epitopes that may have been initially targeted by the subject patient (Table 1) . No T cell responses were detected to some of these epitopes in the ELISPOT screen, but this could potentially be explained by early virologic escape leading to a loss of reactive CD8 + T cells in the subject patient. Discussion. In this study we documented the transmission The differences between the amino acid sequence in the subject patient and that in the transmitter patient are noted, as well as the putative or known HLA restriction of the epitope for the peptides that elicited an IFN-g response from the subject patient (S). Also shown are the other epitopes restricted by HLA alleles that were present in either the subject patient or the transmitter patient (T) in which there were amino acid differences between the 2 patients but to which the subject patient did not respond in the enzyme-linked immunospot assay analysis. HLA-B*5801 epitopes are indicated in boldface font. SFC, spotforming cell.
a Although this peptide partially contains the HLA-B*57/58-restricted KAFSPEVIPMF epitope, no response to the optimal epitope was seen. b No response was seen to the overlapping peptide containing the optimal epitope QASQEVKNW, but a response to the optimal epitope was seen when PBMCs sampled 2 years after infection were used.
of HIV-1 from a patient with progressive disease to an HLA-B*5801-positive patient. Other studies have shown the early development of escape mutations in HLA-B*57/5801-restricted epitopes in Gag [7] [8] [9] [10] and Nef [8, 9] ; we extend those findings by examining the effect of CTL responses on evolution of the entire genome and by documenting the relative predominance of mutations in CTL epitopes. We show for the first time that although escape occurred rapidly in multiple HLA-B*5801-restricted epitopes in 3 different proteins ( Figure 1B ), relative control of viral replication was maintained. Strikingly, all 3 of the substitutions in Gag at day 67 after infection were in CTL epitopes. However, in spite of the strong influence of the CTL response on viral evolution, escape at CTL epitopes did not seem to affect control of viremia: The patient's viral load continued to decline from 4940 copies/mL on day 102 after infection to 1159 copies/mL on day 137. Whereas the T242N mutation in Gag was present at day 67, no escape was seen in the Gag IW9 epitope, although substitutions in this epitope have been shown to occur frequently in primary infection [9, 10] . Conversely, although the KF9 and SW10 epitopes rarely exhibited rapid escape at the population level in a recent study [10] , mutations in both epitopes developed in our patient by day 137 after infection.
Of the 8 independent epitopes in the entire HIV-1 proteome that were targeted on day 221, 3 had developed mutations by that time, including 2 of 4 HLA-B*5801-restricted epitopes. Whereas other studies showed that the development of escape in a high proportion of CTL epitopes targeted during primary infection was associated with progressive disease [11, 12] , our data suggest that early control of viral replication can occur despite the presence of multiple mutations in HLA-B*5801-restricted epitopes. Similar results were seen in a recent study of 2 acutely infected HLA-B*5701-positive patients [13] .
Interestingly, our data also suggest that the presence of the protective HLA-B*5801 allele can supersede the presence of an allele associated with rapid disease progression, in this case HLA-B*5802 [3, 14] . The patient possessed both of these alleles yet failed to mount a response to the HLA-B*5802-restricted epitope in Env that is often targeted by patients with chronic progressive infection [14] . Instead, she exerted impressive though incomplete control over viremia, similar to that seen in HLA-B*57 patients as described elsewhere [15] . Although we do not know whether she would have continued to control viral replication without treatment, it is remarkable that her set-point viral load was so low in the presence of multiple escape mutations.
The data presented here advance our understanding of the important early events that occur during successful spontaneous control, which may be critical for the development of an effective T cell-based vaccine.
